Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + nab-paclitaxel + tegafur gimeracil oteracil potassium
- Development stage
- Unknown
- Lead developer
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This investigational combination regimen consists of bevacizumab, nab-paclitaxel (albumin-bound paclitaxel), and S-1 (a combination of tegafur, gimeracil, and oteracil potassium). Bevacizumab is a recombinant humanized monoclonal antibody that acts as an anti-angiogenic agent by binding to vascular endothelial growth factor (VEGF), preventing its interaction with receptors on endothelial cells. Nab-paclitaxel is a taxane chemotherapy agent that stabilizes microtubules, thereby inhibiting cell division. S-1 is an oral fluoropyrimidine chemotherapy that includes tegafur (a prodrug of 5-fluorouracil), gimeracil (which inhibits the degradation of 5-FU), and oteracil potassium (which reduces gastrointestinal toxicity). This triplet regimen is being evaluated as a second-line therapy for patients with advanced biliary tract adenocarcinoma who have progressed on or are intolerant to first-line treatments.
- Brand names
- TS-1TS1TS 1Teysuno
- Other names
- bevacizumab + nab-paclitaxel + S-1bevacizumab + nab-paclitaxel + tegafur gimeracil oteracil potassium capsule
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + nab-paclitaxel + tegafur gimeracil oteracil potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + nab-paclitaxel + tegafur gimeracil oteracil potassium.